Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

PRIMARY OBJECTIVES: I. Determine the safety and toxicity of the combination of AZD6244 and IMC-A12 in advanced solid tumors that have progressed on standard therapy. II. Finding the maximum tolerated dose (MTD)/recommended phase II dose of the combination. SECONDARY OBJECTIVES: I. Explore preliminary evidence of efficacy of the combination of AZD6244 and IMC-A12 in advanced solid tumors using RECIST criteria for tumor response. II. Define pharmacodynamic (PD) profile of the combination of IMC-A12 and AZD6244. III. Correlate pharmacokinetics (PK) of the combination of IMC-A12 and AZD6244 to pharmacodynamic (PD) endpoints. IV. Assess the PK/PD (phospho-S6) link with AZD6244 when administered in combination with IMC-A12. OUTLINE: This is a dose-escalation study of selumetinib and cixutumumab. Patients receive selumetinib orally (PO) twice daily (BID) on days 1-28 and cixutumumab intravenously (IV) on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks.